NYSE: CLXClorox

    Clorox Q1 FY2027 Results: Net Income $170 Million on Revenue of $1.91 Billion

    • US stocks
    • Earnings
    • Consumer Staples

    Clorox (NYSE: CLX) posted GAAP net sales of $1.91 billion and GAAP net income of $170.0 million for the first quarter of fiscal year 2027, the quarter that closed on 30 Sep 2026, it said on 2 Nov 2026. Diluted EPS was $1.39 on a GAAP basis, and adjusted EPS, a company-defined non-GAAP measure, was $1.55.

    Key highlights

    • Net sales (GAAP): $1.91 billion, up 33.3% YoY
    • Net income (GAAP): $170.0 million, up 112.5% YoY
    • Diluted EPS (GAAP): $1.39 per share, up 113.8% YoY
    • Adjusted EPS (company-defined, non-GAAP): $1.55 per share, up 82% YoY
    • Organic sales growth (non-GAAP): 18%

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ1 FY2027Q1 FY2026YoY
    Revenue1,905.01,429.0+33.3%
    170.080.0+112.5%
    Diluted EPS ($)1.390.65+113.8%

    Figures are in $ million except EPS; YoY compares with Q1 FY2026. Q1 FY2027 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table shows GAAP net sales of $1.91 billion for the quarter, up 33.3% from $1.43 billion a year earlier. The company said the GOJO acquisition contributed about 15 points of that sales growth, and organic sales rose 18%.

    GAAP net income was $170.0 million, up 112.5% from $80.0 million. Net income was 8.9% of revenue this quarter, against 5.6% a year earlier, 3.3 percentage points higher.

    Adjusted EPS excludes GOJO acquisition costs

    The company defines adjusted EPS as a non-GAAP measure. For the quarter it excludes GOJO acquisition and integration costs of about $26 million ($20 million after tax), or $0.16 per share. Adjusted EPS of $1.55 compares with $0.85 a year earlier, and adjusted EBIT, another company-defined measure, was $284.0 million against $160.0 million.

    The year-ago figures excluded about $32 million for the digital capabilities and productivity enhancements investment, which the company completed in the third quarter of fiscal 2026. The company said lapping an ERP transition-related inventory drawdown in the year-ago quarter gave about 18 points of benefit to organic sales growth.

    Every reportable segment grew sales and adjusted EBIT

    Health and Wellness net sales were $918.0 million, up 62%, with segment adjusted EBIT of $209.0 million, up 69%. The company said the GOJO acquisition contributed about 39 points to that segment's sales growth. Household net sales were $423.0 million, up 17%, and segment adjusted EBIT was $30.0 million, up 11%.

    Lifestyle net sales were $283.0 million, up 16%, with segment adjusted EBIT of $60.0 million, up 58%. International net sales were $281.0 million, up 11%, and segment adjusted EBIT was $31.0 million, up 63%.

    Adjusted EPS now expected near the low end of the range

    The company kept its fiscal 2027 net sales growth range of 13% to 14% and its adjusted EPS range of $5.70 to $6.00, but now expects adjusted EPS closer to the low end. Its GAAP diluted EPS range is $5.41 to $5.71.

    The company now expects gross margin of about 41.5%, which it attributes to higher-than-normal inflationary headwinds and negative mix that more than offset cost savings and pricing actions. GAAP gross margin for the quarter was 40.4%, down 130 basis points from 41.7%. The company attributes the decline mainly to higher commodity costs and higher manufacturing and logistics costs, partly offset by higher volume and cost savings.

    Operating cash flow for the year to date reached $143 million, up from $93 million a year earlier, the company said.

    Inference

    Diluted weighted average shares were 122,027 thousand in the quarter, against 123,018 thousand a year earlier. The release does not state share repurchases in the quarter, a dividend declaration, the purchase price of the GOJO acquisition or free cash flow.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts